The Many Faces of PPARγ

In an era marked by the increasing prevalence of obesity, diabetes, and cardiovascular disease, the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ) has emerged as a transcriptional regulator of metabolism whose activity can be modulated by direct binding of small molecules. As the master regulator of fat-cell formation, PPARγ is required for the accumulation of adipose tissue and hence contributes to obesity. Yet PPARγ ligands are clinically effective antidiabetic drugs, although side effects limit their utility. Can PPARγ be targeted with greater benefit and with less risk to patients? The answer depends upon the basic biology of PPARγ, and the possibility of selectively modulating the activity of this nuclear receptor in a tissue- and target-gene-specific manner.

[1]  J. Auwerx,et al.  A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. , 2001, Molecular cell.

[2]  J. C. Hinshaw,et al.  Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Reilly,et al.  Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. , 2003, The Journal of clinical investigation.

[4]  M. Lazar,et al.  A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor γ-activating Properties* , 1998, The Journal of Biological Chemistry.

[5]  R. Evans,et al.  A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .

[6]  L. Rossetti,et al.  Mechanisms of fatty acid-induced inhibition of glucose uptake. , 1994, The Journal of clinical investigation.

[7]  M. Lazar,et al.  The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors , 1999, Nature.

[8]  P. Libby,et al.  PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[9]  T. Willson,et al.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. , 2000, The Journal of clinical investigation.

[10]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. , 1994, Cell.

[11]  Neil J. McKenna,et al.  Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators , 2002, Cell.

[12]  Amir Gamliel,et al.  A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ , 2005, Nature.

[13]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[14]  M. Fu,et al.  Selective disruption of PPARγ2 impairs the development of adipose tissue and insulin sensitivity , 2004 .

[15]  C. Glass,et al.  15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Flier,et al.  Regulated Production of a Peroxisome Proliferator-activated Receptor-γ Ligand during an Early Phase of Adipocyte Differentiation in 3T3-L1 Adipocytes* , 2004, Journal of Biological Chemistry.

[17]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[18]  Andrew C. Li,et al.  Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .

[19]  Jifeng Zhang,et al.  Nitrolinoleic acid: An endogenous peroxisome proliferator-activated receptor γ ligand , 2005 .

[20]  P. Libby,et al.  PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease , 1999 .

[21]  Bruce M. Spiegelman,et al.  Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγ , 1996, Science.

[22]  M. Lazar,et al.  PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1. , 2005, The Journal of clinical investigation.

[23]  M. Lazar,et al.  Peroxisome proliferator-activated receptor γ in diabetes and metabolism , 2004 .

[24]  J. Flier,et al.  Adipose Tissue as an Endocrine Organ , 2014 .

[25]  Jifeng Zhang,et al.  Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Matej Oresic,et al.  The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. , 2005, Diabetes.

[27]  R. Evans,et al.  Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. , 2000, The Journal of clinical investigation.

[28]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. , 2004, The Journal of clinical investigation.

[29]  S. Mandrup,et al.  Adipogenesis: forces that tip the scales , 2002, Trends in Endocrinology & Metabolism.

[30]  R. Evans,et al.  Activators of the nuclear receptor PPARgamma enhance colon polyp formation. , 1998, Nature medicine.

[31]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.

[32]  M. Lazar,et al.  Differential Gene Regulation by PPARγ Agonist and Constitutively Active PPARγ2 , 2002 .

[33]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[34]  M. Lazar,et al.  Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. , 2004, TIPS - Trends in Pharmacological Sciences.

[35]  S. O’Rahilly,et al.  Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.

[36]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[37]  M. Lazar,et al.  Differential gene regulation by PPARgamma agonist and constitutively active PPARgamma2. , 2002, Molecular endocrinology.

[38]  J. Tordjman,et al.  Thiazolidinediones Block Fatty Acid Release by Inducing Glyceroneogenesis in Fat Cells* , 2003, Journal of Biological Chemistry.

[39]  M. Lazar,et al.  Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. , 2005, Genes & development.

[40]  R. Evans,et al.  PPAR gamma is required for placental, cardiac, and adipose tissue development. , 1999, Molecular cell.

[41]  K. Kaestner,et al.  Genetic Modulation of PPARγ Phosphorylation Regulates Insulin Sensitivity , 2003 .

[42]  S. Mudaliar,et al.  Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[43]  K. Kaestner,et al.  Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. , 2003, Developmental cell.

[44]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[45]  S. Grundy,et al.  The metabolic syndrome , 2003, The Lancet.

[46]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[47]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[48]  Margaret S. Wu,et al.  Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological Effects* , 1999, The Journal of Biological Chemistry.

[49]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[50]  B. Ludvik,et al.  Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. , 1994, The New England journal of medicine.

[51]  R. Evans,et al.  Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency , 2000 .

[52]  B. Brewer,et al.  Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. , 2003, The Journal of clinical investigation.

[53]  Reena Rao,et al.  Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption , 2005, Nature Medicine.

[54]  J. Auwerx,et al.  SRC-1 and TIF2 Control Energy Balance between White and Brown Adipose Tissues , 2002, Cell.

[55]  J. Auwerx,et al.  Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARγ hypomorphic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[56]  K. Chien,et al.  PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .

[57]  R. Evans,et al.  A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. , 2001, Molecular cell.

[58]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[59]  L. Chao,et al.  Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. , 2000, The Journal of clinical investigation.

[60]  S. Aizawa,et al.  PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. , 1999, Molecular cell.

[61]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. , 2004, The Lancet. Oncology.

[62]  Peter Beighton,et al.  de la Chapelle, A. , 1997 .

[63]  K. Wellen,et al.  Obesity-induced inflammatory changes in adipose tissue. , 2003, The Journal of clinical investigation.

[64]  S. Tanaka,et al.  Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. , 1998, The Journal of clinical endocrinology and metabolism.

[65]  D. Straus.  15-deoxy Δ^ -PGJ2 inhibits multiple steps in the NF-kappaB signaling pathway , 2000 .

[66]  C. Glass,et al.  Nitric Oxide Synthase Gene-Dependent Repression of the Inducible γ Peroxisome Proliferator-Activated Receptor , 2000 .

[67]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[68]  M. Lazar,et al.  Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. , 2004, The Journal of clinical investigation.

[69]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[70]  C. Glass,et al.  PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[71]  D. Kohan,et al.  Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[72]  M. Lazar,et al.  A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. , 1999, The Journal of clinical investigation.

[73]  T. Osumi,et al.  The transactivating function of peroxisome proliferator‐activated receptor γ is negatively regulated by SUMO conjugation in the amino‐terminal domain , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[74]  B. Spiegelman,et al.  PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .

[75]  B. Frohnert,et al.  Identification of a Functional Peroxisome Proliferator-responsive Element in the Murine Fatty Acid Transport Protein Gene* , 1999, The Journal of Biological Chemistry.

[76]  Millard H. Lambert,et al.  Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα , 2002, Nature.

[77]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[78]  M. Lazar,et al.  A futile metabolic cycle activated in adipocytes by antidiabetic agents , 2002, Nature Medicine.

[79]  M. Fu,et al.  Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[80]  B. Spiegelman,et al.  Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. , 2003, The Journal of clinical investigation.

[81]  M. Lazar,et al.  Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.

[82]  S. Kihara,et al.  Aquaporin 7 deficiency is associated with development of obesity through activation of adipose glycerol kinase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Weimin He,et al.  Muscle-specific Pparg deletion causes insulin resistance , 2003, Nature Medicine.

[84]  M. Jaye,et al.  PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. , 2000, Nature medicine.

[85]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists , 2004 .

[86]  B. Spiegelman,et al.  PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene , 1995, Molecular and cellular biology.

[87]  B. Spiegelman,et al.  PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. , 1999, Molecular cell.

[88]  M. Lazar,et al.  PPARγ regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1 , 2005 .

[89]  B. Spiegelman,et al.  Loss-of-function mutations in PPAR gamma associated with human colon cancer. , 1999, Molecular cell.

[90]  Andrew C. Li,et al.  The macrophage foam cell as a target for therapeutic intervention , 2002, Nature Medicine.

[91]  B. Spiegelman,et al.  Loss-of-Function Mutations in PPARγ Associated with Human Colon Cancer , 1999 .

[92]  Satoshi Tanaka,et al.  PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .

[93]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ , 2004 .

[94]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[95]  J. Auwerx,et al.  Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice , 1998, Nature Medicine.

[96]  Weimin He,et al.  Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle , 2003, Proceedings of the National Academy of Sciences of the United States of America.